Free Trial
→ Elon Musk… A Total Fraud? (From Brownstone Research) (Ad)tc pixel Free BBIO Stock Alerts

BridgeBio Pharma (BBIO) Financials

BridgeBio Pharma logo
$74.95 +4.22 (+5.97%)
Closing price 10/30/2026 04:00 PM Eastern
Extended Trading
$74.65 -0.30 (-0.40%)
As of 10/30/2026 07:55 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare
Annual Income Statements for BridgeBio Pharma

Annual Income Statements for BridgeBio Pharma

This table shows BridgeBio Pharma's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders		 -31 -131 -261 -449 -563 -481 -643 -536 -725
Consolidated Net Income / (Loss)		 -44 -169 -289 -505 -586 -485 -653 -543 -733
Net Income / (Loss) Continuing Operations		 -44 -169 -289 -505 -586 -485 -653 -543 -733
Total Pre-Tax Income 		-44 -169 -289 -505 -586 -485 -653 -542 -733
Total Operating Income		 -44 -184 -266 -474 -577 -512 -607 -593 -523
Total Gross Profit		 0.00 0.00 41 8.25 67 74 6.86 218 481
Total Revenue		 0.00 0.00 41 8.25 70 78 9.30 222 502
Operating Revenue		 0.00 0.00 41 8.25 70 78 9.30 222 502
Total Cost of Revenue		 0.00 0.00 0.00 0.00 3.11 3.43 2.45 3.88 21
Operating Cost of Revenue		 - - 0.00 - 3.11 3.43 2.45 3.88 21
Total Operating Expenses		 44 184 307 483 643 586 614 811 1,005
Selling, General & Admin Expense		 13 44 94 146 192 143 151 289 531
Research & Development Expense		 31 140 210 337 451 399 456 506 452
Restructuring Charge		 - - - 0.00 0.00 44 7.93 16 21
Total Other Income / (Expense), net		 0.03 14 -22 -31 -9.82 28 -46 51 -209
Interest Expense		 0.01 2.55 8.77 37 47 80 81 126 199
Interest & Investment Income		 0.04 21 -12 4.02 1.13 7.54 18 164 -53
Other Income / (Expense), net		 0.00 -4.30 -1.63 1.63 36 100 17 12 43
Income Tax Expense		 - - - - - 0.00 0.00 1.15 0.44
Net Income / (Loss) Attributable to Noncontrolling Interest		 -13 -39 -28 -57 -24 -3.47 -10 -7.59 -8.01
Basic Earnings per Share		 ($1.00) ($2.12) ($2.48) ($3.80) ($3.90) ($3.26) ($3.95) ($2.88) ($3.78)
Weighted Average Basic Shares Outstanding		 30.60M 61.77M 105.10M 118.00M 144.36M 147.47M 162.79M 186.08M 191.53M
Diluted Earnings per Share		 ($1.00) ($2.12) ($2.48) ($3.80) ($3.90) ($3.26) ($3.95) ($2.88) ($3.78)
Weighted Average Diluted Shares Outstanding		 30.60M 61.77M 105.10M 118.00M 144.36M 147.47M 162.79M 186.08M 191.53M
Weighted Average Basic & Diluted Shares Outstanding		 30.60M 61.77M 105.10M 118.00M 144.36M 151.37M 175.83M 190.19M 193.86M

Quarterly Income Statements for BridgeBio Pharma

This table shows BridgeBio Pharma's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026 Q3 2026
Period end date 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026 9/30/2026
Net Income / (Loss) Attributable to Common Shareholders		 -35 -73 -162 -265 -167 -182 -183 -193 -164 -152 -83
Consolidated Net Income / (Loss)		 -36 -76 -164 -267 -170 -184 -185 -195 -167 -156 -60
Net Income / (Loss) Continuing Operations		 -36 -76 -164 -267 -170 -184 -185 -195 -167 -156 -60
Total Pre-Tax Income 		-36 -76 -164 -266 -170 -182 -186 -195 -167 -156 -59
Total Operating Income		 0.34 -176 -192 -226 -104 -134 -145 -140 -106 -107 -12
Total Gross Profit		 211 3.14 2.13 3.80 114 107 114 146 185 229 333
Total Revenue		 211 4.34 2.73 5.88 117 111 121 154 195 244 353
Operating Revenue		 211 4.34 2.73 5.88 117 111 121 154 195 244 353
Total Cost of Revenue		 0.60 1.20 0.60 2.08 2.64 3.65 6.56 8.11 9.94 15 20
Operating Cost of Revenue		 0.60 1.20 0.60 2.08 2.64 3.65 6.56 8.11 9.94 15 20
Total Operating Expenses		 210 177 194 230 218 241 259 286 291 336 344
Selling, General & Admin Expense		 66 60 69 95 106 129 138 158 164 186 201
Research & Development Expense		 141 115 120 130 111 111 113 116 127 149 144
Restructuring Charge		 3.40 2.89 4.62 4.69 0.57 0.81 8.84 11 0.00 0.00 0.00
Total Other Income / (Expense), net		 -37 100 27 -40 -65 -47 -41 -55 -61 -49 -48
Interest Expense		 50 23 23 30 63 38 48 50 53 55 56
Interest & Investment Income		 4.08 124 49 -12 -10 -16 -9.60 -17 -12 0.22 5.79
Other Income / (Expense), net		 9.48 -0.63 1.80 1.62 8.23 6.55 16 12 4.25 5.59 2.12
Income Tax Expense		 - 0.00 0.00 - - 2.10 -1.55 - - 0.00 1.23
Preferred Stock Dividends Declared		 - - - - - - - - - - 26
Net Income / (Loss) Attributable to Noncontrolling Interest		 -0.94 -2.09 -2.21 -2.34 -2.19 -1.86 -2.19 -1.77 -2.51 -3.68 -3.79
Basic Earnings per Share		 ($0.20) ($0.39) ($0.86) ($1.43) ($0.88) ($0.95) ($0.95) ($1.00) ($0.84) ($0.78) ($0.42)
Weighted Average Basic Shares Outstanding		 178.71M 187.59M 188.51M 186.08M 190.15M 190.52M 191.85M 191.53M 194.79M 195.79M 196.03M
Diluted Earnings per Share		 ($0.20) ($0.39) ($0.86) ($1.43) ($0.88) ($0.95) ($0.95) ($1.00) ($0.84) ($0.78) ($0.42)
Weighted Average Diluted Shares Outstanding		 178.71M 187.59M 188.51M 186.08M 190.15M 190.52M 191.85M 191.53M 194.79M 195.79M 196.03M
Weighted Average Basic & Diluted Shares Outstanding		 187.13M 188.03M 188.99M 190.19M 189.88M 191.17M 192.71M 193.86M 195.86M 195.49M 194.80M

Annual Cash Flow Statements for BridgeBio Pharma

This table details how cash moves in and out of BridgeBio Pharma's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents		 72 344 -72 -5.52 38 21 -22 289 -111
Net Cash From Operating Activities		 -40 -137 -254 -400 -498 -419 -528 -521 -446
Net Cash From Continuing Operating Activities		 -40 -137 -254 -400 -498 -419 -529 -521 -446
Net Income / (Loss) Continuing Operations		 -44 -169 -289 -505 -586 -485 -653 -543 -733
Consolidated Net Income / (Loss)		 -44 -169 -289 -505 -586 -485 -653 -543 -733
Depreciation Expense		 - - 0.86 1.46 5.84 6.77 6.49 6.08 5.43
Amortization Expense		 - 0.00 - - - - 13 7.46 5.97
Non-Cash Adjustments To Reconcile Net Income		 2.10 10 45 86 61 30 100 -23 320
Changes in Operating Assets and Liabilities, net		 1.24 22 -11 18 21 28 5.06 32 -45
Net Cash From Investing Activities		 -0.46 -21 -217 -53 -201 453 54 61 -24
Net Cash From Continuing Investing Activities		 -0.46 -21 -217 -53 -201 453 54 61 -24
Purchase of Property, Plant & Equipment		 -0.46 -2.18 -2.64 -7.52 -13 -4.82 -1.31 -0.93 -1.10
Acquisitions		 0.00 -16 0.00 0.00 -35 -1.50 0.00 -8.12 -8.50
Purchase of Investments		 0.00 0.00 -213 -288 -643 -193 -137 -114 -28
Sale and/or Maturity of Investments		 - 0.00 0.00 249 477 533 193 184 13
Net Cash From Financing Activities		 113 502 399 447 736 -13 452 748 359
Net Cash From Continuing Financing Activities		 113 502 397 447 733 -13 452 748 359
Repayment of Debt		 0.13 55 -0.82 -13 -140 -20 0.00 -489 -471
Repurchase of Common Equity		 0.00 0.00 0.00 -75 -200 - 0.00 0.00 -48
Payment of Dividends		 -1.15 -44 -55 -5.00 - - -0.80 0.00 2.15
Issuance of Debt		 4.00 1.00 37 550 1,204 0.00 0.00 450 575
Issuance of Common Equity		 0.00 96 391 25 3.82 7.41 453 319 6.41
Other Financing Activities, net		 2.98 59 25 -35 -49 -0.90 -0.87 469 295
Cash Interest Paid		 0.00 1.57 6.09 15 30 54 61 91 44
Cash Income Taxes Paid		 - - - - - - 0.00 0.00 1.20

Quarterly Cash Flow Statements for BridgeBio Pharma

This table details how cash moves in and out of BridgeBio Pharma's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026 Q3 2026
Period end date 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026 9/30/2026
Net Change in Cash & Equivalents		 83 72 -142 275 -141 208 -106 -73 310 -202 855
Net Cash From Operating Activities		 -220 75 -181 -195 -199 -81 -110 -56 -197 -71 -44
Net Cash From Continuing Operating Activities		 -220 75 -181 -195 -199 -81 -110 -56 -197 -71 -44
Net Income / (Loss) Continuing Operations		 -36 -76 -164 -267 -170 -184 -185 -195 -167 -156 -60
Consolidated Net Income / (Loss)		 -36 -76 -164 -267 -170 -184 -185 -195 -167 -156 -60
Depreciation Expense		 1.60 1.57 1.54 1.37 1.28 1.32 1.40 1.44 1.19 1.05 1.07
Amortization Expense		 - - - - 1.62 - - 1.45 1.82 1.93 1.93
Non-Cash Adjustments To Reconcile Net Income		 40 137 -16 56 84 82 73 79 91 87 89
Changes in Operating Assets and Liabilities, net		 -225 12 -2.32 14 -116 19 -3.93 56 -125 -5.62 -75
Net Cash From Investing Activities		 23 3.04 38 -3.24 -1.60 -13 4.46 -14 -43 18 37
Net Cash From Continuing Investing Activities		 23 3.04 38 -3.24 -1.60 -13 4.46 -14 -43 18 37
Purchase of Property, Plant & Equipment		 -0.70 -0.05 -0.14 -0.05 0.00 -0.59 -0.47 -0.03 -0.07 -0.44 -0.29
Sale and/or Maturity of Investments		 89 55 40 - 0.00 - 10 3.00 10 30 37
Net Cash From Financing Activities		 280 -5.73 0.71 474 60 302 -0.89 -2.18 550 -149 863
Net Cash From Continuing Financing Activities		 280 -5.73 0.71 474 60 302 -0.89 -2.18 550 -149 863
Repurchase of Common Equity		 0.00 - - - -48 - - - -83 -128 -44
Payment of Dividends		 - - - - 0.80 - - 0.60 0.00 - -2.69
Issuance of Common Equity		 318 -0.50 2.12 - 3.24 - 3.18 - 5.47 - 4.26
Other Financing Activities, net		 -2.40 -1.50 -1.41 474 0.75 302 1.28 -9.68 19 -32 -29
Cash Interest Paid		 35 14 29 13 23 - 20 - 20 - 23

Annual Balance Sheets for BridgeBio Pharma

This table presents BridgeBio Pharma's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Total Assets		 465 632 704 1,013 623 546 919 936
Total Current Assets		 445 569 643 889 549 478 721 798
Cash & Equivalents		 436 364 356 394 377 376 681 570
Short-Term Investments		 0.00 182 251 443 95 59 0.00 17
Accounts Receivable		 - 2.85 - - - 1.75 4.72 139
Inventories, net		 - - - - - - 0.00 27
Prepaid Expenses		 9.14 20 36 32 22 24 35 44
Plant, Property, & Equipment, net		 1.58 5.63 20 30 15 12 7.01 5.37
Total Noncurrent Assets		 18 57 40 94 60 57 192 133
Long-Term Investments		 17 31 - - - 0.00 144 80
Intangible Assets		 - - 0.00 45 29 26 24 28
Other Noncurrent Operating Assets		 1.09 26 40 49 31 31 24 25
Total Liabilities & Shareholders' Equity		 465 632 704 1,013 623 546 919 936
Total Liabilities		 88 156 596 1,878 1,868 1,889 2,377 3,013
Total Current Liabilities		 33 60 96 135 121 144 154 288
Short-Term Debt		 - 0.00 1.46 - - - - 0.00
Accounts Payable		 14 8.85 8.95 12 12 11 9.62 36
Accrued Expenses		 12 26 46 81 67 66 34 41
Current Deferred Revenue		 - - - 0.00 8.16 6.10 15 7.19
Current Employee Benefit Liabilities		 4.05 13 30 37 31 57 58 77
Other Current Liabilities		 3.01 12 9.35 4.94 3.68 4.13 38 126
Total Noncurrent Liabilities		 55 95 500 1,743 1,747 1,745 2,223 2,725
Long-Term Debt		 55 92 92 431 431 446 1,721 1,852
Noncurrent Deferred Revenue		 - - - - - 3.73 17 13
Other Noncurrent Operating Liabilities		 0.50 3.53 408 1,313 1,316 1,295 484 859
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Redeemable Noncontrolling Interest		 0.12 2.24 1.63 1.42 -1.59 0.48 0.14 -0.57
Total Equity & Noncontrolling Interests		 377 474 106 -867 -1,243 -1,343 -1,458 -2,076
Total Preferred & Common Equity		 315 408 58 -870 -1,255 -1,354 -1,468 -2,087
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 315 408 58 -870 -1,255 -1,354 -1,468 -2,087
Common Stock		 494 848 1,021 842 939 1,481 1,903 2,058
Retained Earnings		 -179 -440 -889 -1,437 -1,918 -2,561 -3,096 -3,821
Treasury Stock		 - 0.00 -75 -275 -275 -275 -275 -323
Accumulated Other Comprehensive Income / (Loss)		 0.00 0.25 0.19 -0.13 -0.33 0.03 0.01 0.01
Noncontrolling Interest		 62 65 48 3.41 11 11 10 11

Quarterly Balance Sheets for BridgeBio Pharma

This table presents BridgeBio Pharma's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q2 2023 Q3 2023 Q1 2024 Q2 2024 Q3 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026 Q2 2026 Q3 2026
Period end date 6/30/2023 9/30/2023 3/31/2024 6/30/2024 9/30/2024 3/31/2025 6/30/2025 9/30/2025 3/31/2026 6/30/2026 9/30/2026
Total Assets		 504 655 849 794 665 882 1,080 998 1,371 1,217 2,162
Total Current Assets		 433 588 783 616 445 695 912 839 1,241 1,093 2,045
Cash & Equivalents		 302 505 475 408 266 541 749 643 880 678 1,533
Short-Term Investments		 81 38 44 40 0.00 - 7.94 2.99 60 42 5.49
Accounts Receivable		 - - - - - 115 77 117 205 254 375
Inventories, net		 - - - - - 3.95 18 25 33 53 60
Prepaid Expenses		 21 23 28 28 38 35 60 52 63 66 71
Plant, Property, & Equipment, net		 13 12 11 9.84 8.70 6.70 6.11 5.83 4.94 5.23 5.04
Total Noncurrent Assets		 58 55 54 168 212 180 162 153 125 119 112
Long-Term Investments		 - - - 117 160 128 108 92 62 55 48
Intangible Assets		 28 27 26 25 25 28 30 29 27 27 26
Other Noncurrent Operating Assets		 30 28 29 26 27 24 24 32 36 37 38
Total Liabilities & Shareholders' Equity		 504 655 849 794 665 882 1,080 998 1,371 1,217 2,162
Total Liabilities		 1,853 1,849 1,886 1,876 1,883 2,520 2,859 2,921 3,640 3,723 3,815
Total Current Liabilities		 110 106 141 134 139 152 176 217 816 891 977
Short-Term Debt		 - - - - - - - - 547 548 548
Accounts Payable		 3.87 4.47 4.73 18 13 28 26 19 29 27 88
Accrued Expenses		 68 57 86 67 66 34 31 35 54 64 55
Current Deferred Revenue		 6.21 6.59 14 15 12 12 11 9.09 6.12 5.55 4.74
Current Employee Benefit Liabilities		 29 34 32 29 44 33 37 56 39 50 67
Other Current Liabilities		 3.78 4.14 4.54 4.62 4.60 46 71 98 140 196 214
Total Noncurrent Liabilities		 1,743 1,743 1,745 1,742 1,744 2,368 2,683 2,704 2,823 2,833 2,838
Long-Term Debt		 440 442 435 435 436 0.00 0.00 1,851 1,926 1,928 1,929
Noncurrent Deferred Revenue		 - - 20 17 19 18 15 13 12 10 8.97
Other Noncurrent Operating Liabilities		 1,303 1,301 1,290 1,290 1,289 2,351 2,668 840 886 895 900
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Redeemable Noncontrolling Interest		 0.33 1.40 0.53 -0.22 0.65 -0.23 -0.45 0.02 -0.95 -1.02 -1.36
Total Equity & Noncontrolling Interests		 -1,350 -1,195 -1,037 -1,082 -1,219 -1,638 -1,778 -1,923 -2,268 -2,505 -1,652
Total Preferred & Common Equity		 -1,362 -1,208 -1,050 -1,093 -1,230 -1,648 -1,788 -1,933 -2,278 -2,515 -1,662
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 942
Total Common Equity		 -1,362 -1,208 -1,050 -1,093 -1,230 -1,648 -1,788 -1,933 -2,278 -2,515 -2,605
Common Stock		 1,128 1,460 1,821 1,851 1,876 1,939 1,981 2,019 2,113 2,156 2,170
Retained Earnings		 -2,215 -2,392 -2,596 -2,669 -2,831 -3,264 -3,446 -3,628 -3,985 -4,137 -4,194
Treasury Stock		 -275 -275 -275 -275 -275 -323 -323 -323 -406 -533 -581
Accumulated Other Comprehensive Income / (Loss)		 0.06 0.03 0.00 -0.00 0.01 0.00 0.00 0.00 -0.01 -0.01 -0.10
Noncontrolling Interest		 12 12 12 11 11 9.96 9.89 10 10 10 10

Annual Metrics And Ratios for BridgeBio Pharma

This table displays calculated financial ratios and metrics derived from BridgeBio Pharma's official financial filings.

Metric 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Growth Metrics		 - - - - - - - - -
Revenue Growth		 0.00% 0.00% 0.00% -79.66% 745.14% 11.38% -88.02% 2,285.27% 126.26%
EBITDA Growth		 0.00% -328.56% -42.06% -76.55% -13.49% 24.30% -44.08% 1.52% 17.32%
EBIT Growth		 0.00% -328.56% -42.51% -76.52% -14.37% 23.86% -43.29% 1.58% 17.28%
NOPAT Growth		 0.00% -318.76% -44.96% -78.22% -21.53% 11.17% -18.58% 2.37% 11.73%
Net Income Growth		 0.00% -286.59% -70.31% -75.16% -16.02% 17.36% -34.79% 16.82% -34.89%
EPS Growth		 0.00% -112.00% -16.98% -53.23% -2.63% 16.41% -21.17% 27.09% -31.25%
Operating Cash Flow Growth		 0.00% -237.49% -85.58% -57.62% -24.57% 15.75% -25.80% 1.33% 14.37%
Free Cash Flow Firm Growth		 0.00% 0.00% -84.78% 132.19% 625.00% -166.23% -30.97% 120.57% 97.01%
Invested Capital Growth		 0.00% 0.00% 55.94% -4,225.81% -213.74% -4.10% -1.80% -36.93% -58.90%
Revenue Q/Q Growth		 0.00% 0.00% 0.00% -62.41% 22.41% -12.42% -1.33% 1.90% 42.79%
EBITDA Q/Q Growth		 0.00% 0.00% 0.00% -10.36% -2.24% 3.06% -5.62% -13.64% 17.96%
EBIT Q/Q Growth		 0.00% 0.00% 0.00% -10.70% -2.43% 2.98% -5.54% -13.43% 16.75%
NOPAT Q/Q Growth		 0.00% 0.00% 0.00% -11.48% -7.08% 6.63% -8.62% -8.93% 14.18%
Net Income Q/Q Growth		 0.00% 0.00% 0.00% -11.19% -3.03% 2.36% -4.77% -21.75% 9.03%
EPS Q/Q Growth		 0.00% 0.00% 0.00% -12.09% 0.26% 2.69% -1.54% -19.01% 10.21%
Operating Cash Flow Q/Q Growth		 0.00% 0.00% -13.31% -5.28% -8.18% 8.83% -6.36% -15.66% 23.75%
Free Cash Flow Firm Q/Q Growth		 0.00% 0.00% 0.00% 0.00% -2.43% 80.97% -144.75% 123.95% 96.28%
Invested Capital Q/Q Growth		 0.00% 0.00% 0.00% -1.61% -1.73% -5,495.73% -2.72% -36.85% -10.09%
Profitability Metrics		 - - - - - - - - -
Gross Margin		 0.00% 0.00% 100.00% 100.00% 95.53% 95.58% 73.71% 98.25% 95.82%
EBITDA Margin		 0.00% 0.00% -658.30% -5,714.54% -767.35% -521.57% -6,272.23% -258.95% -93.40%
Operating Margin		 0.00% 0.00% -656.41% -5,751.99% -827.12% -659.65% -6,528.75% -267.22% -104.25%
EBIT Margin		 0.00% 0.00% -660.42% -5,732.19% -775.73% -530.29% -6,342.04% -261.69% -95.67%
Profit (Net Income) Margin		 0.00% 0.00% -711.50% -6,127.87% -841.20% -624.17% -7,021.94% -244.86% -145.98%
Tax Burden Percent		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.21% 100.06%
Interest Burden Percent		 99.94% 90.15% 107.73% 106.90% 108.44% 117.70% 110.72% 93.37% 152.49%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 0.00% -44.90% -67.64% -173.15% 154.80% 45.93% 50.49% 38.81% 41.48%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)		 0.00% 0.00% -48.85% -70.82% -63.02% -50.34% -100.91% -79.24% -51.78%
Return on Assets (ROA)		 0.00% 0.00% -52.63% -75.71% -68.34% -59.25% -111.72% -74.14% -79.01%
Return on Common Equity (ROCE)		 0.00% -37.47% -57.33% -138.31% 166.00% 46.24% 50.91% 39.11% 41.72%
Return on Equity Simple (ROE_SIMPLE)		 0.00% -53.81% -70.65% -872.95% 67.38% 38.63% 48.24% 37.02% 0.00%
Net Operating Profit after Tax (NOPAT)		 -31 -129 -186 -332 -404 -359 -425 -415 -366
NOPAT Margin		 0.00% 0.00% -459.49% -4,026.40% -578.98% -461.75% -4,570.13% -187.06% -72.97%
Net Nonoperating Expense Percent (NNEP)		 0.00% -20.51% -23.13% -34.72% -39.77% -52.01% -543.39% -65.32% 35.22%
Return On Investment Capital (ROIC_SIMPLE)		 - - - - - 44.14% 47.42% 40.68% 163.90%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 4.47% 4.42% 26.29% 1.75% 4.18%
SG&A Expenses to Revenue		 0.00% 0.00% 232.63% 1,766.08% 275.70% 184.41% 1,618.73% 130.21% 105.81%
R&D to Revenue		 0.00% 0.00% 517.62% 4,085.91% 646.94% 514.45% 4,898.54% 228.24% 90.02%
Operating Expenses to Revenue		 0.00% 0.00% 756.41% 5,851.99% 922.65% 755.22% 6,602.46% 365.48% 200.07%
Earnings before Interest and Taxes (EBIT)		 -44 -188 -268 -473 -541 -412 -590 -581 -480
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -44 -188 -267 -471 -535 -405 -584 -575 -469
Valuation Ratios		 - - - - - - - - -
Price to Book Value (P/BV)		 0.00 1.11 10.60 150.52 0.00 0.00 0.00 0.00 0.00
Price to Tangible Book Value (P/TBV)		 0.00 1.11 10.60 150.52 0.00 0.00 0.00 0.00 0.00
Price to Revenue (P/Rev)		 0.00 0.00 106.79 1,056.59 35.21 14.67 754.92 23.37 29.36
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 96.49 1,000.44 29.46 13.78 755.64 21.67 31.74
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 129.31 4.44 0.00 0.00 58.26 0.00
Leverage & Solvency		 - - - - - - - - -
Debt to Equity		 0.00 0.14 0.19 0.87 -0.50 -0.35 -0.33 -0.30 -0.89
Long-Term Debt to Equity		 0.00 0.14 0.19 0.86 -0.50 -0.35 -0.33 -0.30 -0.89
Financial Leverage		 0.00 -1.06 -1.04 -1.71 1.21 0.23 0.03 0.14 -0.59
Leverage Ratio		 0.00 1.23 1.29 2.29 -2.27 -0.78 -0.45 -0.52 -0.53
Compound Leverage Factor		 0.00 1.11 1.38 2.44 -2.46 -0.91 -0.50 -0.49 -0.80
Debt to Total Capital		 0.00% 12.62% 16.17% 46.53% -99.06% -52.95% -49.82% -42.86% -826.59%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.72% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 12.62% 16.17% 45.81% -99.06% -52.95% -49.82% -42.86% -826.59%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 14.47% 11.89% 24.77% -1.11% -1.19% -1.31% -1.01% -4.48%
Common Equity to Total Capital		 0.00% 72.91% 71.94% 28.70% 200.17% 154.14% 151.13% 143.87% 931.06%
Debt to EBITDA		 0.00 -0.29 -0.34 -0.20 -0.81 -1.06 -0.77 -0.76 -3.95
Net Debt to EBITDA		 0.00 2.12 1.82 1.09 0.76 0.19 0.01 0.67 -2.53
Long-Term Debt to EBITDA		 0.00 -0.29 -0.34 -0.20 -0.81 -1.06 -0.77 -0.76 -3.95
Debt to NOPAT		 0.00 -0.42 -0.49 -0.28 -1.07 -1.20 -1.05 -1.05 -5.06
Net Debt to NOPAT		 0.00 3.10 2.60 1.55 1.01 0.22 0.01 0.93 -3.23
Long-Term Debt to NOPAT		 0.00 -0.42 -0.49 -0.28 -1.07 -1.20 -1.05 -1.05 -5.06
Altman Z-Score		 0.00 1.58 15.35 5.74 -2.00 -5.18 -7.14 -4.51 -3.28
Noncontrolling Interest Sharing Ratio		 0.00% 16.56% 15.23% 20.13% -7.23% -0.69% -0.83% -0.79% -0.58%
Liquidity Ratios		 - - - - - - - - -
Current Ratio		 0.00 13.67 9.42 6.72 6.58 4.52 3.32 4.67 2.77
Quick Ratio		 0.00 13.39 9.09 6.35 6.34 4.03 3.04 4.44 2.52
Cash Flow Metrics		 - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 0.00 -107 -198 64 463 -306 -401 83 -36
Operating Cash Flow to CapEx		 -8,725.86% -6,273.78% -9,612.85% -5,316.76% -3,759.13% 0.00% -40,407.35% -55,812.00% -40,648.13%
Free Cash Flow to Firm to Interest Expense		 0.00 -42.13 -22.62 1.74 9.89 -3.81 -4.94 0.66 -0.18
Operating Cash Flow to Interest Expense		 -3,114.46 -53.65 -28.93 -10.90 -10.64 -5.22 -6.49 -4.14 -2.24
Operating Cash Flow Less CapEx to Interest Expense		 -3,150.15 -54.50 -29.23 -11.11 -10.93 -5.15 -6.51 -4.14 -2.24
Efficiency Ratios		 - - - - - - - - -
Asset Turnover		 0.00 0.00 0.07 0.01 0.08 0.09 0.02 0.30 0.54
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 68.56 6.97
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.00 0.00 11.27 0.64 2.77 3.48 0.71 23.57 81.13
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.30 0.29 0.22 0.38 0.91
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 5.32 52.40
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 1,220.71 1,245.83 1,657.35 954.05 399.15
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 -1,220.71 -1,245.83 -1,657.35 -948.73 -346.74
Capital & Investment Metrics		 - - - - - - - - -
Invested Capital		 0.00 -21 -9.37 -405 -1,272 -1,324 -1,348 -1,845 -892
Invested Capital Turnover		 0.00 0.00 -2.65 -0.04 -0.08 -0.06 -0.01 -0.14 -0.69
Increase / (Decrease) in Invested Capital		 0.00 -21 12 -396 -866 -52 -24 -498 -330
Enterprise Value (EV)		 0.00 12 3,913 8,253 2,053 1,070 7,030 4,809 15,935
Market Capitalization		 349 349 4,331 8,716 2,455 1,139 7,023 5,186 14,740
Book Value per Share		 $0.00 $5.10 $3.31 $0.47 ($5.91) ($8.39) ($7.78) ($7.77) ($10.83)
Tangible Book Value per Share		 $0.00 $5.10 $3.31 $0.47 ($6.22) ($8.59) ($7.94) ($7.89) ($10.97)
Total Capital		 0.00 432 568 202 -435 -814 -896 -1,020 -224
Total Debt		 0.00 55 92 94 431 431 446 437 1,852
Total Long-Term Debt		 0.00 55 92 92 431 431 446 437 1,852
Net Debt		 0.00 -399 -485 -513 -406 -79 -5.09 -388 1,185
Capital Expenditures (CapEx)		 0.46 2.18 2.64 7.52 13 -5.18 1.31 0.93 1.10
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 0.00 -23 -38 -58 -83 -82 -118 -115 -78
Debt-free Net Working Capital (DFNWC)		 0.00 413 508 549 754 427 334 566 510
Net Working Capital (NWC)		 0.00 413 508 547 754 427 334 566 510
Net Nonoperating Expense (NNE)		 13 41 102 173 183 126 228 128 367
Net Nonoperating Obligations (NNO)		 0.00 -399 -485 -513 -406 -79 -5.09 -388 1,185
Total Depreciation and Amortization (D&A)		 0.00 0.00 0.86 1.46 5.84 6.77 6.49 6.08 11
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% 0.00% -93.09% -708.68% -119.13% -106.15% -1,266.13% -51.80% -15.48%
Debt-free Net Working Capital to Revenue		 0.00% 0.00% 1,253.05% 6,650.92% 1,081.23% 550.46% 3,587.54% 255.20% 101.53%
Net Working Capital to Revenue		 0.00% 0.00% 1,253.05% 6,633.24% 1,081.23% 550.46% 3,587.54% 255.20% 101.53%
Earnings Adjustments		 - - - - - - - - -
Adjusted Basic Earnings per Share		 $0.00 $0.00 ($2.48) ($3.80) ($3.90) ($3.26) ($3.95) ($2.88) ($3.78)
Adjusted Weighted Average Basic Shares Outstanding		 0.00 0.00 123.77M 148.96M 147.61M 147.47M 162.79M 186.08M 191.53M
Adjusted Diluted Earnings per Share		 $0.00 $0.00 ($2.48) ($3.80) ($3.90) ($3.26) ($3.95) ($2.88) ($3.78)
Adjusted Weighted Average Diluted Shares Outstanding		 0.00 0.00 123.77M 148.96M 147.61M 147.47M 162.79M 186.08M 191.53M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 ($2.48) ($3.80) ($3.90) $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 0.00 0.00 105.10M 118.00M 144.36M 151.37M 175.83M 190.19M 193.86M
Normalized Net Operating Profit after Tax (NOPAT)		 -31 -129 -186 -332 -404 -328 -420 -404 -351
Normalized NOPAT Margin		 0.00% 0.00% -459.49% -4,026.40% -578.98% -422.30% -4,510.49% -182.13% -70.00%
Pre Tax Income Margin		 0.00% 0.00% -711.50% -6,127.87% -841.20% -624.17% -7,021.94% -244.34% -145.89%
Debt Service Ratios		 - - - - - - - - -
EBIT to Interest Expense		 -3,373.69 -73.80 -30.56 -12.90 -11.56 -5.12 -7.26 -4.61 -2.41
NOPAT to Interest Expense		 -2,361.58 -50.48 -21.26 -9.06 -8.63 -4.46 -5.23 -3.30 -1.84
EBIT Less CapEx to Interest Expense		 -3,409.38 -74.65 -30.86 -13.11 -11.84 -5.05 -7.27 -4.62 -2.41
NOPAT Less CapEx to Interest Expense		 -2,397.28 -51.33 -21.56 -9.27 -8.91 -4.39 -5.25 -3.30 -1.84
Payout Ratios		 - - - - - - - - -
Dividend Payout Ratio		 -2.63% -26.10% -19.06% -0.99% 0.00% 0.00% 0.00% 0.00% 0.29%
Augmented Payout Ratio		 -2.63% -26.10% -19.06% -15.83% -34.10% 0.00% 0.00% 0.00% -6.29%

Quarterly Metrics And Ratios for BridgeBio Pharma

This table displays calculated financial ratios and metrics derived from BridgeBio Pharma's official financial filings.

Metric Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026 Q3 2026
Period end date 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026 9/30/2026
DEI Shares Outstanding		 - - - - - - - - 193,862,871.00 195,861,242.00 195,487,474.00
DEI Adjusted Shares Outstanding		 - - - - - - - - 193,862,871.00 195,861,242.00 195,487,474.00
DEI Earnings Per Adjusted Shares Outstanding		 - - - - - - - - -0.85 -0.78 -0.42
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 11,461.88% 32.11% -33.22% 237.08% -44.76% 2,449.93% 4,318.01% 4,051.27% 66.78% 120.39% 192.60%
EBITDA Growth		 109.13% -22.11% -16.78% -44.78% -930.48% 27.60% 32.42% 44.82% -5.86% 21.18% 94.81%
EBIT Growth		 107.75% -21.81% -16.55% -44.18% -1,078.43% 27.50% 32.23% 43.07% -5.79% 20.54% 92.60%
NOPAT Growth		 100.27% -20.15% -21.60% -27.40% -30,529.15% 23.51% 24.28% 38.25% -1.52% 20.26% 91.98%
Net Income Growth		 74.67% 52.99% 8.49% -56.98% -369.05% -143.25% -12.59% 27.21% 1.80% 15.17% 67.29%
EPS Growth		 78.26% 60.20% 20.37% -47.42% -340.00% -143.59% -10.47% 30.07% 4.55% 17.89% 55.79%
Operating Cash Flow Growth		 -52.12% 165.90% -24.33% -56.49% 9.25% -208.00% 39.32% 71.12% 0.98% 11.87% 59.69%
Free Cash Flow Firm Growth		 -141.29% -107.24% -108.30% 438.23% 745.11% 1,511.46% -554.50% 124.64% -242.44% -259.59% 91.37%
Invested Capital Growth		 13.34% -2.89% -2.78% -36.93% -105.66% -95.68% 39.94% -58.90% 65.46% 69.52% 5.82%
Revenue Q/Q Growth		 11,998.57% -98.97% 26.01% 115.30% 1,882.88% -5.20% 9.17% 27.74% 26.16% 25.27% 44.93%
EBITDA Q/Q Growth		 107.41% -1,628.60% -7.91% -18.37% 57.47% -33.27% -0.73% 1.95% 20.95% 0.19% 93.37%
EBIT Q/Q Growth		 106.31% -1,892.91% -7.82% -18.14% 57.16% -32.86% -0.79% 0.77% 20.39% 0.21% 90.62%
NOPAT Q/Q Growth		 100.19% -51,277.55% -9.24% -17.88% 53.82% -28.65% -8.13% 3.88% 24.08% -1.06% 89.13%
Net Income Q/Q Growth		 78.77% -108.92% -117.43% -62.79% 36.57% -8.34% -0.64% -5.24% 14.43% 6.40% 61.19%
EPS Q/Q Growth		 79.38% -95.00% -120.51% -66.28% 38.46% -7.95% 0.00% -5.26% 16.00% 7.14% 46.15%
Operating Cash Flow Q/Q Growth		 -75.88% 134.03% -341.71% -8.17% -2.00% 59.50% -35.81% 48.51% -249.66% 63.96% 37.88%
Free Cash Flow Firm Q/Q Growth		 -71.85% 50.76% -15.19% 447.01% 227.76% 7.74% -153.41% 136.36% -780.69% -20.70% 97.11%
Invested Capital Q/Q Growth		 16.75% -20.40% 0.18% -36.85% -25.05% -14.56% 69.36% -10.09% 10.60% -1.08% 5.33%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 99.72% 72.42% 78.11% 64.57% 97.74% 96.70% 94.56% 94.74% 94.89% 93.83% 94.21%
EBITDA Margin		 5.41% -8,053.37% -6,896.60% -3,791.84% -81.33% -114.33% -105.50% -80.98% -50.74% -40.43% -1.85%
Operating Margin		 0.16% -8,096.82% -7,018.67% -3,842.69% -89.49% -121.45% -120.30% -90.52% -54.47% -43.94% -3.30%
EBIT Margin		 4.65% -8,125.97% -6,952.89% -3,815.08% -82.43% -115.52% -106.66% -82.85% -52.29% -41.65% -2.70%
Profit (Net Income) Margin		 -17.13% -3,484.50% -6,012.23% -4,545.89% -145.42% -166.20% -153.22% -126.24% -85.63% -63.97% -17.13%
Tax Burden Percent		 100.00% 100.00% 100.00% 100.43% 100.00% 101.16% 99.17% 99.94% 100.00% 100.00% 102.07%
Interest Burden Percent		 -368.00% 42.88% 86.47% 118.64% 176.42% 142.22% 144.85% 152.46% 163.77% 153.60% 622.36%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 48.58% 37.96% 37.00% 38.81% 50.59% 54.89% 51.30% 41.48% 37.36% 32.77% 32.30%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)		 1.38% -2,743.52% -2,294.11% -1,155.17% -12.14% -28.80% -45.10% -44.84% -26.92% -25.85% -1.61%
Return on Assets (ROA)		 -5.08% -1,176.45% -1,983.74% -1,376.45% -21.41% -41.43% -64.78% -68.32% -44.09% -39.71% -10.25%
Return on Common Equity (ROCE)		 49.12% 38.32% 37.39% 39.11% 51.02% 55.27% 51.66% 41.72% 37.54% 32.92% 40.99%
Return on Equity Simple (ROE_SIMPLE)		 52.09% 42.23% 36.29% 0.00% 41.06% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 0.24 -123 -134 -158 -73 -94 -102 -98 -74 -75 -8.15
NOPAT Margin		 0.11% -5,667.77% -4,913.07% -2,689.88% -62.64% -85.01% -84.21% -63.36% -38.13% -30.76% -2.31%
Net Nonoperating Expense Percent (NNEP)		 -43.82% 40.81% -24.20% -55.60% -25.61% -15.84% 16.95% 9.31% 23.01% 19.38% 5.23%
Return On Investment Capital (ROIC_SIMPLE)		 - - - 15.51% 4.46% 5.29% 141.69% 43.70% -36.07% 255.06% -0.99%
Cost of Revenue to Revenue		 0.28% 27.58% 21.89% 35.43% 2.26% 3.30% 5.44% 5.26% 5.11% 6.17% 5.79%
SG&A Expenses to Revenue		 31.17% 2,745.53% 2,519.00% 1,611.39% 91.20% 116.81% 114.02% 102.53% 84.26% 76.44% 56.87%
R&D to Revenue		 66.77% 5,290.36% 4,408.64% 2,216.08% 95.54% 100.60% 93.52% 75.51% 65.10% 61.33% 40.63%
Operating Expenses to Revenue		 99.55% 8,169.23% 7,096.78% 3,907.26% 187.22% 218.14% 214.86% 185.26% 149.36% 137.77% 97.51%
Earnings before Interest and Taxes (EBIT)		 9.83 -176 -190 -224 -96 -128 -129 -128 -102 -101 -9.52
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 11 -175 -188 -223 -95 -126 -127 -125 -99 -99 -6.53
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Price to Tangible Book Value (P/TBV)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Price to Revenue (P/Rev)		 24.61 21.63 21.98 23.37 51.60 35.09 28.24 29.36 24.82 20.46 13.60
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 24.28 20.45 21.44 21.67 46.43 31.43 31.43 31.74 27.38 22.86 15.55
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 58.26 8.49 8.82 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 -0.42 -0.40 -0.36 -0.30 0.00 0.00 -0.96 -0.89 -1.09 -0.99 -1.50
Long-Term Debt to Equity		 -0.42 -0.40 -0.36 -0.30 0.00 0.00 -0.96 -0.89 -0.85 -0.77 -1.17
Financial Leverage		 0.07 0.10 0.10 0.14 0.28 0.40 -0.31 -0.59 -0.21 -0.20 -0.56
Leverage Ratio		 -0.66 -0.53 -0.55 -0.52 -0.65 -0.66 -0.53 -0.53 -0.58 -0.54 -0.88
Compound Leverage Factor		 2.41 -0.23 -0.47 -0.62 -1.14 -0.93 -0.77 -0.80 -0.94 -0.82 -5.50
Debt to Total Capital		 -72.20% -67.34% -55.77% -42.86% 0.00% 0.00% -2,581.14% -826.59% 1,208.47% -8,141.71% 300.69%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 267.47% -1,802.19% 66.56%
Long-Term Debt to Total Capital		 -72.20% -67.34% -55.77% -42.86% 0.00% 0.00% -2,581.14% -826.59% 940.99% -6,339.53% 234.13%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 114.39%
Noncontrolling Interests to Total Capital		 -2.10% -1.68% -1.47% -1.01% -0.59% -0.53% -14.42% -4.48% 4.64% -30.66% 1.07%
Common Equity to Total Capital		 174.30% 169.01% 157.24% 143.87% 100.59% 100.53% 2,695.56% 931.06% -1,113.10% 8,272.37% -316.15%
Debt to EBITDA		 -0.97 -0.91 -0.86 -0.76 0.00 0.00 -3.24 -3.95 -5.21 -5.53 -7.54
Net Debt to EBITDA		 0.19 0.56 0.26 0.67 0.00 0.00 -1.95 -2.53 -3.10 -3.80 -2.71
Long-Term Debt to EBITDA		 -0.97 -0.91 -0.86 -0.76 0.00 0.00 -3.24 -3.95 -4.06 -4.30 -5.87
Debt to NOPAT		 -1.29 -1.22 -1.14 -1.05 0.00 0.00 -4.34 -5.06 -6.73 -7.10 -9.72
Net Debt to NOPAT		 0.25 0.75 0.34 0.93 0.00 0.00 -2.61 -3.23 -4.01 -4.88 -3.49
Long-Term Debt to NOPAT		 -1.29 -1.22 -1.14 -1.05 0.00 0.00 -4.34 -5.06 -5.24 -5.53 -7.57
Altman Z-Score		 -1.37 -2.92 -4.50 -3.23 -3.09 -2.10 -2.37 -2.04 -1.15 -1.90 0.32
Noncontrolling Interest Sharing Ratio		 -1.10% -0.95% -1.05% -0.79% -0.84% -0.71% -0.70% -0.58% -0.49% -0.44% -26.89%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 5.54 4.59 3.19 4.67 4.57 5.19 3.88 2.77 1.52 1.23 2.09
Quick Ratio		 5.34 3.34 1.92 4.44 4.31 4.74 3.52 2.52 1.40 1.09 1.96
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -172 -85 -98 339 1,112 1,198 -640 233 -1,585 -1,913 -55
Operating Cash Flow to CapEx		 -31,588.06% 138,338.89% -131,800.00% -415,587.23% 0.00% -13,582.66% -23,313.62% -170,969.70% -285,911.59% -16,049.89% -15,231.03%
Free Cash Flow to Firm to Interest Expense		 -3.44 -3.70 -4.24 11.38 17.58 31.84 -13.30 4.63 -30.00 -35.01 -0.99
Operating Cash Flow to Interest Expense		 -4.39 3.26 -7.83 -6.55 -3.15 -2.14 -2.28 -1.12 -3.74 -1.30 -0.80
Operating Cash Flow Less CapEx to Interest Expense		 -4.40 3.25 -7.84 -6.55 -3.15 -2.16 -2.29 -1.12 -3.74 -1.31 -0.80
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.30 0.34 0.33 0.30 0.15 0.25 0.42 0.54 0.51 0.62 0.60
Accounts Receivable Turnover		 0.00 0.00 0.00 68.56 0.00 0.00 0.00 6.97 3.62 4.30 3.85
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.53 1.12 1.27
Fixed Asset Turnover		 17.50 19.15 20.63 23.57 14.07 29.30 48.39 81.13 99.66 125.84 173.94
Accounts Payable Turnover		 0.54 0.22 0.27 0.38 0.37 0.38 0.89 0.91 1.00 1.49 1.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 5.32 0.00 0.00 0.00 52.40 100.85 84.80 94.89
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 238.50 327.30 287.15
Days Payable Outstanding (DPO)		 671.43 1,678.51 1,360.74 954.05 994.45 964.36 408.05 399.15 365.38 245.46 364.58
Cash Conversion Cycle (CCC)		 -671.43 -1,678.51 -1,360.74 -948.73 -994.45 -964.36 -408.05 -346.74 -26.03 166.65 17.46
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 -1,122 -1,351 -1,348 -1,845 -2,307 -2,643 -810 -892 -797 -806 -763
Invested Capital Turnover		 -0.18 -0.16 -0.16 -0.14 -0.07 -0.12 -0.33 -0.69 -0.37 -0.41 -1.20
Increase / (Decrease) in Invested Capital		 173 -38 -36 -498 -1,185 -1,292 539 -330 1,510 1,838 47
Enterprise Value (EV)		 5,307 4,482 4,669 4,809 5,916 7,344 11,053 15,935 15,878 16,297 14,705
Market Capitalization		 5,379 4,740 4,787 5,186 6,575 8,199 9,929 14,740 14,396 14,588 12,863
Book Value per Share		 ($5.87) ($5.84) ($6.54) ($7.77) ($8.67) ($9.42) ($10.11) ($10.83) ($11.75) ($12.84) ($13.32)
Tangible Book Value per Share		 ($6.02) ($5.97) ($6.67) ($7.89) ($8.81) ($9.57) ($10.26) ($10.97) ($11.89) ($12.98) ($13.46)
Total Capital		 -602 -647 -782 -1,020 -1,639 -1,778 -72 -224 205 -30 824
Total Debt		 435 435 436 437 0.00 0.00 1,851 1,852 2,474 2,475 2,477
Total Long-Term Debt		 435 435 436 437 0.00 0.00 1,851 1,852 1,926 1,928 1,929
Net Debt		 -85 -269 -130 -388 -669 -865 1,113 1,185 1,472 1,700 891
Capital Expenditures (CapEx)		 0.70 0.05 0.14 0.05 0.00 0.59 0.47 0.03 0.07 0.44 0.29
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 122 -105 -100 -115 2.47 -20 -23 -78 32 30 77
Debt-free Net Working Capital (DFNWC)		 642 482 305 566 543 736 623 510 972 750 1,616
Net Working Capital (NWC)		 642 482 305 566 543 736 623 510 425 202 1,067
Net Nonoperating Expense (NNE)		 36 -47 30 109 97 90 83 97 92 81 52
Net Nonoperating Obligations (NNO)		 -85 -269 -130 -388 -669 -865 1,113 1,185 1,472 1,700 891
Total Depreciation and Amortization (D&A)		 1.60 1.57 1.54 1.37 1.28 1.32 1.40 2.89 3.01 2.98 2.99
Debt-free, Cash-free Net Working Capital to Revenue		 55.87% -48.06% -46.09% -51.80% 1.94% -8.76% -6.59% -15.48% 5.56% 4.25% 8.14%
Debt-free Net Working Capital to Revenue		 293.67% 219.91% 140.23% 255.20% 426.22% 315.19% 177.12% 101.53% 167.67% 105.24% 170.89%
Net Working Capital to Revenue		 293.67% 219.91% 140.23% 255.20% 426.22% 315.19% 177.12% 101.53% 73.27% 28.40% 112.88%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($0.20) ($0.39) ($0.86) ($1.43) ($0.88) ($0.95) ($0.95) ($1.00) ($0.84) ($0.78) ($0.42)
Adjusted Weighted Average Basic Shares Outstanding		 178.71M 187.59M 188.51M 186.08M 190.15M 190.52M 191.85M 191.53M 194.79M 195.79M 196.03M
Adjusted Diluted Earnings per Share		 ($0.20) ($0.39) ($0.86) ($1.43) ($0.88) ($0.95) ($0.95) ($1.00) ($0.84) ($0.78) ($0.42)
Adjusted Weighted Average Diluted Shares Outstanding		 178.71M 187.59M 188.51M 186.08M 190.15M 190.52M 191.85M 191.53M 194.79M 195.79M 196.03M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 187.13M 188.03M 188.99M 190.19M 189.88M 191.17M 192.71M 193.86M 195.86M 195.49M 194.80M
Normalized Net Operating Profit after Tax (NOPAT)		 2.62 -121 -131 -155 -73 -93 -95 -90 -74 -75 -8.15
Normalized NOPAT Margin		 1.24% -5,574.43% -4,794.67% -2,634.03% -62.30% -84.50% -79.08% -58.31% -38.13% -30.76% -2.31%
Pre Tax Income Margin		 -17.13% -3,484.50% -6,012.23% -4,526.28% -145.42% -164.30% -154.50% -126.32% -85.63% -63.97% -16.78%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 0.20 -7.68 -8.24 -7.53 -1.52 -3.39 -2.67 -2.54 -1.93 -1.86 -0.17
NOPAT to Interest Expense		 0.00 -5.36 -5.82 -5.31 -1.15 -2.50 -2.11 -1.94 -1.40 -1.37 -0.15
EBIT Less CapEx to Interest Expense		 0.18 -7.68 -8.24 -7.53 -1.52 -3.41 -2.68 -2.54 -1.93 -1.87 -0.18
NOPAT Less CapEx to Interest Expense		 -0.01 -5.36 -5.83 -5.31 -1.15 -2.51 -2.12 -1.94 -1.41 -1.38 -0.15
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.29% 0.19% 0.09% -0.36%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -6.29% -11.12% -29.83% -44.31%

Financials Breakdown Chart

Key Financial Trends

BridgeBio Pharma’s financial profile has improved on the revenue front, but the company remains unprofitable and highly leveraged. Revenue has expanded sharply from low single-digit millions in 2022 and 2023 to $243.7 million in Q2 2026. However, quarterly results remain volatile, likely reflecting collaboration, licensing or milestone-related revenue rather than a consistently recurring base.

  • Revenue momentum remains strong. Q2 2026 revenue of $243.7 million increased 25.2% from $194.5 million in Q1 2026 and 120.4% from $110.6 million in Q2 2025. Revenue has risen substantially from the $1.7 million to $5.9 million quarterly range reported during much of 2022 through 2024.
  • Gross profitability has scaled with revenue. Q2 2026 gross profit was $228.6 million, representing a gross margin of approximately 93.8%. The company has maintained very high gross margins in recent quarters as revenue has increased.
  • Operating and net losses improved year over year. Q2 2026 operating loss was $107.1 million, compared with $134.3 million in Q2 2025. Net loss narrowed to $155.9 million from $183.8 million, while loss per share improved to $0.78 from $0.95.
  • Operating cash burn improved sequentially and year over year. Cash used in operating activities was $71.1 million in Q2 2026, down from $197.3 million in Q1 2026 and $80.7 million in Q2 2025. This indicates that the company’s cash consumption is beginning to moderate, although it remains significant.
  • Liquidity remains substantial in absolute terms. BridgeBio reported $677.9 million of cash and equivalents at June 30, 2026, plus $42.2 million of short-term investments and $55.1 million of long-term investments. Accounts receivable also rose to $254.5 million, providing additional potential near-term collections, though receivables may not be immediately convertible to cash.
  • Quarterly revenue and cash flow are highly uneven. Revenue surged from $5.9 million in Q4 2024 to $116.6 million in Q1 2025, then reached $243.7 million in Q2 2026. Investors should avoid extrapolating any single quarter without determining how much revenue is recurring versus milestone- or transaction-driven.
  • The company continues to post substantial losses. BridgeBio recorded a $155.9 million net loss attributable to common shareholders in Q2 2026. Research and development expense was $149.4 million and selling, general and administrative expense was $186.3 million, together exceeding gross profit by more than $107 million.
  • Cash declined significantly during Q2. Net cash decreased by $202.0 million in Q2 2026, despite $17.9 million of positive investing cash flow. The decline was driven primarily by operating cash burn and $148.8 million of financing cash outflows, including a $127.5 million common-stock repurchase and $32.1 million of other financing outflows.
  • Debt and interest costs have become major financial burdens. Current debt stood at $548.0 million and long-term debt at $1.93 billion at the end of Q2 2026. Interest expense reached $54.6 million for the quarter, up from $37.6 million in Q2 2025 and $20.0 million in Q4 2022. Debt issuance helped fund prior operations, but leverage now increases refinancing and liquidity risk.
  • Shareholders’ equity remains deeply negative. Total common equity was negative $2.52 billion at June 30, 2026, compared with negative $1.79 billion in Q2 2025 and negative $1.14 billion in Q2 2024. Retained earnings were negative $4.14 billion, while total liabilities of $3.72 billion substantially exceeded total assets of $1.22 billion.

The balance sheet shows a current ratio of approximately 1.23 based on $1.09 billion of current assets and $890.6 million of current liabilities. That provides some near-term working-capital coverage, but the ratio should be viewed alongside the company’s continuing operating losses, falling cash balance and large debt obligations.

Overall, BridgeBio’s revenue growth and improving gross profit are constructive developments, and the Q2 reduction in operating cash burn is encouraging. Still, the investment case depends heavily on continued revenue growth, successful development programs and access to additional financing. The combination of persistent losses, negative equity, rising interest expense and volatile cash generation remains a significant risk for BBIO shareholders.

11/01/26 02:09 PM ETAI Generated. May Contain Errors.

BridgeBio Pharma Financials - Frequently Asked Questions

According to the most recent income statement we have on file, BridgeBio Pharma's fiscal year ends in December. Their fiscal year 2025 ended on December 31, 2025.

BridgeBio Pharma's net income appears to be on a downward trend, with a most recent value of -$732.94 million in 2025, falling from -$43.83 million in 2017. The previous period was -$543.35 million in 2024. Check out BridgeBio Pharma's forecast to explore projected trends and price targets.

BridgeBio Pharma's total operating income in 2025 was -$523.41 million, based on the following breakdown:
  • Total Gross Profit: $481.11 million
  • Total Operating Expenses: $1.00 billion

Over the last 8 years, BridgeBio Pharma's total revenue changed from $0.00 in 2017 to $502.08 million in 2025, a change of 50,207,600,000.0%.

In the past 13 quarters, BridgeBio Pharma's cash and equivalents has ranged from $266.32 million in Q3 2024 to $1.53 billion in Q3 2026, and is currently $1.53 billion as of their latest financial filing in Q3 2026.

BridgeBio Pharma had total debt of $1.85 billion at the end of 2025, a 323.6% increase from 2024, and none in 2017.

Over the last 8 years, BridgeBio Pharma's book value per share changed from 0.00 in 2017 to -10.83 in 2025.


Related Companies

Financial statements for NASDAQ:BBIO last updated on 10/29/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners
The most dangerous moment in a financial crisis
Dr. Martin D. Weiss has publicly predicted six major American crashes since founding Weiss Ratings in 1971. ...
Weiss Ratings | Sponsoredtc pixel
The 401k Email 70 Million Investors Might Delete
An email announcing a new 401k investment option is headed to roughly 70 million inboxes. Most recipients will...
Brownstone Research | Sponsoredtc pixel
Your free stock pick for today
Elon Musk doesn't own the chip powering every Tesla, every Starlink dish, and every AI satellite he builds, he...
Behind the Markets | Sponsoredtc pixel
The investigation Porter spent tens of thousands to document
Porter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experi...
Porter & Company | Sponsoredtc pixel
Cigar Lake Flooded Again Uranium Supply Shock Repeats
In 2006, a flooded mine at Cigar Lake sent uranium prices from the 50 range to 136 in eight months. This pa...
Digest Publishing | Sponsoredtc pixel
Last call for your free 0DTE report
The 0DTE Game Plan lays out a simple 3-step framework for trading same-day options: Plan it, profit from it, p...
Profits Run | Sponsoredtc pixel
Does your nest egg have an expiration date?
A $250,000 nest egg growing at 5% a year and paying out $2,500 a month runs dry in just over a decade. Start w...
Investors Alley | Sponsoredtc pixel
Crypto’s price fell... this number didn’t
Something strange is happening with one crypto right now… Its price? Down. Dragged lower with the rest of the ...
Crypto 101 Media | Sponsoredtc pixel